Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1,662 MXN
Change Today 0.00 / 0.00%
Volume 0.0
NVSN On Other Exchanges
SIX Swiss Ex
SIX Swiss Ex
As of 4:09 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-sponsored adr (NVSN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/27/15 - $1,662
52 Week Low
08/7/14 - $1,134
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

novartis ag-sponsored adr (NVSN) Related Businessweek News

View More BusinessWeek News

novartis ag-sponsored adr (NVSN) Details

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company’s Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

120,000 Employees
Last Reported Date: 07/21/15
Founded in 1895

novartis ag-sponsored adr (NVSN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.6.1M
Chief Financial Officer
Total Annual Compensation: SFr.2.6M
President of Institutes for Biomedical Resear...
Total Annual Compensation: $3.0M
Global Head of Novartis Business Services and...
Total Annual Compensation: SFr.1.2M
Division Head of Novartis Pharmaceuticals
Total Annual Compensation: $3.9M
Compensation as of Fiscal Year 2014.

novartis ag-sponsored adr (NVSN) Key Developments

Novartis Announces That the US Food and Drug Administration Approves Entresto Tablets

Novartis announced that the US Food and Drug Administration (FDA) has approved Entresto(TM) (sacubitril/valsartan) tablets, previously known as LCZ696, for the treatment of heart failure with reduced ejection fraction. Entresto will be available on prescription for patients whose condition is classified NYHA class II-IV, indicated to reduce the risk of cardiovascular death and heart failure hospitalization. It is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other angiotensin receptor blocker. The FDA's decision is based on results from the 8,442-patient PARADIGM-HF study which was stopped early when it was shown Entresto significantly reduced the risk of cardiovascular death versus ACE-inhibitor enalapril. At the end of the study, patients with reduced ejection fraction who were given Entresto were more likely to be alive and less likely to have been hospitalized for heart failure than those given enalapril. Analysis of safety data showed that Entresto had a similar tolerability profile to enalapril. Entresto is currently undergoing review by Health Authorities around the world, including in Canada, Switzerland and the EU. Once approved by health authorities around the world, Entresto could achieve estimated peak sales in excess of $5 billion for the reduced ejection fraction indication.

Novartis Announces Publication in the Lancet Showing Sustained Efficacy with Secukinumab over One Year in Psoriatic Arthritis Patients

Novartis announced that new one year results from the pivotal Phase III FUTURE 2 study of secukinumab in psoriatic arthritis (PsA) were published in The Lancet following fast-track review. Secukinumab is the first interleukin-17A (IL-17A) inhibitor to demonstrate efficacy in a Phase III study in adult patients with active PsA.[1] PsA is a long-term, debilitating, inflammatory disease associated with joint pain and stiffness, skin and nail psoriasis, swollen toes and fingers, persistent painful tendonitis and irreversible joint damage. The new study results published in The Lancet show improvements observed with subcutaneous secukinumab 300 mg and 150 mg were sustained over one year of treatment in the majority of patients (64% for both doses), as measured by the American College of Rheumatology response criteria (ACR 20). Moreover, ACR 50 response rates were also sustained to one year in secukinumab 300 mg and 150 mg (44% and 39% respectively). Secukinumab met the primary endpoint of the study, which was ACR 20 at Week 24 with response rates significantly higher in the secukinumab 300 mg (54%; p<0.0001) and 150 mg (51%; p<0.0001) groups versus placebo (15%), with clinical improvements observed as early as Week 3. ACR 20 and 50 are standard tools used to assess improvement of PsA signs and symptoms, and represent a 20% and 50% improvement from baseline, respectively. Secukinumab 300 mg and 150 mg also significantly improved a key secondary endpoint which was improvement in psoriasis symptoms, as measured by 90% improvements in Psoriasis Area and Severity Index score (PASI 90). Achieving PASI 90 means that patients can attain clear to almost clear skin. This is important as the majority of people living with PsA have a history of, or concomitant, psoriasis, another long-term condition which is characterized by thick and extensive skin lesions, called plaques, known to cause itching, scaling and pain. Although the secukinumab benefits seen in FUTURE 2 were generally higher in patients without previous treatment with standard of care anti-TNF therapy, clinical benefits were observed in both anti-TNF-na?ve patients and those with an inadequate response to anti-TNFs. This is important as many patients do not respond to, or tolerate these therapies and approximately 40% of people are dissatisfied with current treatments. There is therefore, a high unmet need for patients with PsA. Secukinumab was well tolerated in FUTURE 2, with a safety profile consistent with that observed in the psoriasis clinical trial program involving nearly 5,000 patients. The most common adverse events (AEs) were upper respiratory tract infections and the common cold.

US Seeks Up to USD 3.35 Billion in Novartis AG Kickback Lawsuit

The United States says Novartis AG should pay as much as USD 3.35 billion in damages and civil fines because the drugmaker used kickbacks to boost sales of two drugs covered by Medicare and Medicaid. In papers filed in Manhattan federal court, the government said it deserves that sum under the federal False Claims Act over alleged improper reimbursements for Exjade, used by patients who receive blood transfusions, and Myfortic, for patients with kidney transplants. The government is seeking up to USD 1.52 billion in damages, representing triple the sums allegedly reimbursed and tainted by kickbacks between 2004 and 2013. It also wants as much as USD 1.83 billion in fines, equal to USD 5,500 to USD 11,000 for each of the 166,031 allegedly false claims submitted for reimbursement. Novartis continues to dispute the allegations and is continuing to defend itself in this litigation. A jury trial is scheduled to begin on November 2 and could last several weeks, court papers show. The government often settles False Claims Act cases before trial. Novartis is being sued by the federal government, 11 intervening U.S. states, and David Kester, a whistleblower and former Novartis respiratory account manager acting on behalf of 17 other states. The lawsuit accuses Novartis of paying kickbacks, in the form of rebates, to three specialty pharmacies to induce them to recommend refills of Exjade, which is intended to reduce iron levels in patients. It also accuses the drugmaker of offering similar rebates to five other pharmacies to induce them to recommend Myfortic, an immunosuppressant, over rival drugs including Roche Holding AG's CellCept and generic equivalents. The intervening states also alleged state law claims with respect to Exjade.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVSN:MM $1,661.80 MXN 0.00

NVSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $331.15 USD +2.28
Amgen Inc $176.59 USD +4.90
Gilead Sciences Inc $117.86 USD -0.04
Johnson & Johnson $100.21 USD +0.37
Nestle SA SFr.73.20 CHF +0.30
View Industry Companies

Industry Analysis


Industry Average

Valuation NVSN Industry Range
Price/Earnings 26.3x
Price/Sales 4.9x
Price/Book 3.2x
Price/Cash Flow 14.2x
TEV/Sales 4.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at